Share on StockTwits
 

AstraZeneca (NYSE:AZN) was upgraded by investment analysts at Danske from a “sell” rating to a “buy” rating in a note issued to investors on Wednesday, Analyst Ratings Network reports.

A number of other analysts have also recently weighed in on AZN. Analysts at Morgan Stanley upgraded shares of AstraZeneca to an “equal weight” rating in a research note to investors on Tuesday. Separately, analysts at Leerink Swann upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. They now have a $68.00 price target on the stock, up previously from $55.00. Finally, analysts at UBS AG initiated coverage on shares of AstraZeneca in a research note to investors on Thursday, January 9th. They set a “buy” rating on the stock. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average price target of $59.04.

AstraZeneca (NYSE:AZN) traded up 1.16% during mid-day trading on Wednesday, hitting $62.89. 944,212 shares of the company’s stock traded hands. AstraZeneca has a one year low of $44.46 and a one year high of $62.35. The stock’s 50-day moving average is $58.09 and its 200-day moving average is $52.74. The company has a market cap of $78.801 billion and a price-to-earnings ratio of 16.76.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by $0.06. The company had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.45 billion. During the same quarter in the previous year, the company posted $1.51 earnings per share. The company’s revenue for the quarter was down 6.5% on a year-over-year basis. Analysts expect that AstraZeneca will post $5.07 EPS for the current fiscal year.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.